“Ridding the Race of His Defective Blood”—Eugenics in the Journal, 1906–1948
By Paul A. Lombardo,
The New England Journal of Medicine
| 03. 02. 2024
In 1923, Boston City Hospital chose Dr. William Mayo, already famous for the work of his Minnesota clinic, to speak at the inauguration of a new laboratory. Mayo’s thoughts on hospital administration, published in the Boston Medical and Surgical Journal (which would be renamed the New England Journal of Medicine in 1928), highlighted the common anxieties of his profession and went far beyond the anodyne comments that were usual on such occasions.1 Mayo amplified the phobias and fed the moral panic stemming from the eugenic thought of that time, saying that municipal hospitals were swamped by the poor, as cities were besieged by criminals and the country threatened with demise by waves of defective immigrants. While Congress debated increased restriction on immigration, Mayo traced poverty to “constitutional inferiority and mental instability,” declaring both “to a large extent hereditary.”
Mayo said one goal of public hospitals should be to “reduce the number of people whom it must care for at the expense of the taxpayer.” A robust sterilization program and limits on immigration of the “defective” would serve that goal...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...